In lung adenocarcinoma, the main molecular pathway implicated in the drug action was a downregulation of eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1), known to play critical roles in the tumorigenesis and progression of solid tumors [110]. This evidence concerns the gene EIF4EBP1 and lung adenocarcinoma.